Japan’s MHLF approves Padcev with Keytruda for first-line treatment of radically unresectable urothelial carcinoma: Tokyo Wednesday, September 25, 2024, 11:00 Hrs [IST] Astellas ...
An FDA advisory panel on Bristol Myers Squibb Opdivo and Merck Keytruda will examine if PD-L1 tumor expression should limit ...
"If patients with low or no PD-L1 expression are not expected to benefit based on the available data, then administering anti ...
Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...
(OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the first patient enrolled in a Phase I dose ...
Is there any difference in efficacy with Keytruda (pembrolizumab) on three-week intervals versus six-week intervals? No. In ...
New anecdotal evidence suggests some chemoimmunotherapy treatments may improve pulmonary arterial hypertension symptoms, but the overall evidence remains murky.
Few companies have attracted more attention this year than Nvidia. The chipmaker is on a roll thanks to the rapid rise of ...
Shares of Bicara Therapeutics—a biopharmaceutical company backed by Indian billionaire Kiran Mazumdar-Shaw—surged about 42% ...
The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...
Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback